What is an HIV-1 Genotypic Resistance test, and how does it analyze the RT and Protease parts of the virus?

Understanding HIV and its relationship with antiretroviral therapy can feel complex, particularly when terms such as "drug resistance" arise. For individuals living with HIV, or those exploring testing options, awareness of an HIV-1 genotypic resistance test can be genuinely valuable. This article explains what this test involves, how it analyses key regions of the virus — particularly the Reverse Transcriptase (RT) and Protease genes — and when testing may be considered.

Our clinic provides confidential STI testing services. We do not provide GP services or dermatology consultations, but we can advise on appropriate next steps if further medical care is needed.

Quick Answer: What Does an HIV-1 Genotypic Resistance Test Do?

An HIV-1 genotypic resistance test analyses specific regions of the HIV genome to identify mutations that may cause resistance to antiretroviral drugs. It primarily examines the Reverse Transcriptase (RT) and Protease gene regions, where resistance-associated mutations most commonly occur.

Key points at a glance:

• Identifies genetic mutations in the HIV-1 virus
• Focuses on the RT and Protease gene regions
• Helps inform antiretroviral treatment decisions
• Performed using a blood sample
• Results interpreted by specialist clinicians

Resistance testing results alone do not determine treatment. They inform clinical decisions made alongside other factors.

When Might HIV-1 Drug Resistance Be a Concern?

Drug resistance in HIV-1 can develop when the virus replicates in the presence of antiretroviral medication, particularly if treatment is interrupted, doses are missed, or a person acquires a strain already carrying resistance mutations. In some cases, transmitted resistance — where a newly acquired strain already carries mutations — may also be a consideration.

Resistance is not always present, and its significance depends on individual clinical history, viral load, and the specific antiretroviral drugs involved.

Section 1: Understanding HIV-1 and the Concept of Drug Resistance

HIV-1 is a retrovirus that replicates rapidly within the body. During replication, errors can occur in the viral genome, producing mutations. Some of these mutations affect the regions of the virus targeted by antiretroviral drugs, potentially reducing their effectiveness.

The HIV-1 genotypic resistance test sequences specific parts of the viral genome to identify which mutations are present. This information can help clinicians understand whether particular drugs are likely to remain effective.

Section 2: What Are the RT and Protease Regions?

Reverse Transcriptase (RT)

Reverse Transcriptase is an enzyme HIV uses to convert its RNA genome into DNA — an essential step in its replication cycle. Many antiretroviral drug classes target this enzyme, including:

• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Mutations in the RT gene region can reduce the binding or activity of these drugs, potentially limiting their effectiveness.

Protease

The Protease enzyme is responsible for cleaving viral proteins into their functional forms — a critical step for producing mature, infectious viral particles. Protease Inhibitors (PIs) are a class of antiretroviral drugs designed to block this enzyme.

Mutations in the Protease gene region can alter the enzyme's structure, reducing how effectively Protease Inhibitors bind to and block it.

Section 3: How Does the Genotypic Resistance Test Work?

The HIV-1 genotypic resistance test is performed on a blood sample. The process generally involves the following steps:

1. Blood draw — A venous blood sample is collected.
2. RNA extraction — HIV RNA is extracted from the plasma portion of the blood.
3. Amplification (PCR) — The RT and Protease gene regions are amplified using polymerase chain reaction (PCR) techniques.
4. Sequencing — The amplified regions are sequenced to identify the exact genetic code present.
5. Mutation analysis — The sequence is compared against known resistance mutation databases (such as the Stanford HIV Drug Resistance Database) to identify clinically significant mutations.
6. Interpretation — Results are interpreted in the context of established resistance algorithms, producing susceptibility predictions for various antiretroviral drugs.

Results are typically reported as susceptible, intermediate resistance, or high-level resistance for each drug class assessed.

Section 4: STIs and HIV — Understanding the Broader Context

HIV is classified as a sexually transmitted infection (STI), though it can also be transmitted through sharing needles or from mother to child during pregnancy, birth, or breastfeeding. For individuals who are sexually active and concerned about HIV exposure, an HIV test may provide important clarity.

It is worth noting that other STIs can sometimes increase susceptibility to HIV transmission. Conditions such as herpes, syphilis, or gonorrhoea can cause inflammation or ulceration that may facilitate transmission. A full STI screen is available for those who wish to assess their overall sexual health.

Section 5: How Do HIV Symptoms Overlap With Other Conditions?

Early HIV infection — sometimes referred to as acute HIV or primary HIV infection — can produce symptoms that overlap significantly with other conditions. These may include:

• Fever and flu-like symptoms
• Swollen lymph nodes
• Fatigue
• Rash

Importantly, symptoms alone cannot confirm HIV infection or any other STI. Many conditions produce similar presentations. Testing is the only way to obtain clarity. Symptom presence or absence does not reliably indicate infection status.

Section 6: When Might HIV or Resistance Testing Be Sensible?

Consideration of HIV or HIV resistance testing may be relevant in circumstances such as:

• Recent unprotected sexual contact with a new or unknown partner
• Concern about potential HIV exposure
• A partner receiving an HIV diagnosis
• Being newly diagnosed with HIV and beginning treatment planning
• Detectable viral load whilst on antiretroviral therapy
• Clinical suspicion of treatment failure

These decisions are best made in consultation with an appropriate healthcare professional.

Section 7: How STI and HIV Testing Works at a Private Clinic

Private STI testing typically involves a straightforward and confidential process:

• Blood tests — Used for HIV, syphilis, hepatitis B, and hepatitis C
• Urine tests — Commonly used for chlamydia and gonorrhoea
• Swab tests — Used for herpes, gonorrhoea, and other localised infections
• Results — Provided confidentially, often via secure online portal or telephone

HIV resistance testing requires a separate specialist process beyond a standard HIV test and is typically arranged through an HIV specialist or sexual health physician following an HIV diagnosis.

Section 8: When HIV-Related Concerns Are Less Likely

Not every concern about HIV exposure will result in a positive test. Many individuals who test following a perceived risk receive a negative result. Factors that may reduce risk include:

• Use of barrier contraception (condoms)
• Low or undetectable viral load in a partner on effective treatment (Undetectable = Untransmittable, U=U)
• Post-exposure prophylaxis (PEP) taken promptly following exposure

Testing remains the only way to confirm status.

Frequently Asked Questions

Q: What is an HIV-1 genotypic resistance test?

A: It is a laboratory test that sequences specific HIV gene regions — primarily RT and Protease — to identify mutations associated with resistance to antiretroviral drugs. Results help inform treatment decisions.

Q: Does a positive HIV test automatically mean drug resistance is present?

A: No. Drug resistance is not always present following an HIV diagnosis. Resistance testing is a separate process conducted to assess suitability of specific antiretroviral regimens.

Q: Can I request an HIV resistance test privately?

A: HIV resistance testing is a specialist investigation, typically arranged following an HIV diagnosis and in coordination with an HIV clinician. Standard HIV testing is available privately. If a positive result is received, onward specialist referral would be appropriate.

Q: How is the HIV-1 genotypic resistance test different from a standard HIV test?

A: A standard HIV test detects the presence of HIV antibodies or antigens in the blood. A genotypic resistance test analyses the genetic sequence of the virus itself to identify specific mutations — it is only relevant for those already confirmed to have HIV.

Q: Should I test even if I have no symptoms?

A: HIV can be present without symptoms, sometimes for years. If there has been potential exposure, testing is a sensible consideration regardless of symptom status.

Q: How soon after potential exposure should HIV testing be done?

A: This depends on the type of test used. Most modern combination (4th generation) HIV tests can detect infection from around 45 days post-exposure. Earlier testing may be advised in some circumstances. Guidance from a healthcare professional is recommended.

Section 10: When to Seek Medical Advice

Certain situations may warrant prompt consultation with an appropriate healthcare service, including:

• Severe or rapidly worsening symptoms
• Persistent fever, unexplained weight loss, or night sweats
• Sores, ulcers, or lesions that do not resolve
• Concerns about treatment failure if already on antiretroviral therapy

If symptoms persist or worsen, consultation with an appropriate healthcare service may be advised.

Confidential STI Testing in the UK

If you are concerned about possible HIV exposure or wish to understand your sexual health status, confidential STI testing appointments are available at our UK clinic. Testing decisions depend on symptoms, exposure history, and individual risk factors.

For further information about our services, visit sticlinic.co.uk or explore our main testing hub.

Medical Disclaimer: This article is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Sexual health concerns should be assessed based on individual circumstances. If you are experiencing persistent, severe, or worsening symptoms, consultation with an appropriate healthcare service is advised. Our clinic provides private STI testing services only.